Tezspire and Eye Pain After Injections
Eye pain is not a recognized adverse event associated with Tezspire (tezepelumab) injections based on available FDA labeling and clinical trial data. The provided evidence does not document ocular pain, eye discomfort, or injection site reactions involving the eyes as adverse effects of tezepelumab.
What the Evidence Shows
Tezspire Safety Profile
The most comprehensive pharmacovigilance analysis of tezepelumab identified 2,153 adverse event reports across 256 preferred terms, but eye pain was not among the significant adverse events reported 1. The most frequent adverse events were arthralgia and dyspnea, with injection site reactions being uncommon (occurring in only 1-3% of participants depending on delivery device) 2.
Injection Site Characteristics
When tezepelumab is administered subcutaneously to the abdomen, thigh, or upper arm:
- Median injection site pain score was 2 mm on a 0-100 mm visual analog scale immediately after injection
- Pain resolved to 0 mm within 30 minutes across all injection sites
- Injection site reactions were rare (1.0-2.9% depending on device)
- No ocular or periocular injection sites are used 2
Clinical Approach
If a Patient Reports Eye Pain After Tezspire:
Consider alternative etiologies first:
- Coincidental conjunctivitis, dry eye, or allergic eye disease (common in asthma patients)
- Unrelated ocular conditions
- Systemic inflammatory conditions
Assess severity and characteristics:
- Duration and timing relative to injection
- Associated symptoms (redness, discharge, vision changes, photophobia)
- Bilateral vs unilateral presentation
Initial management:
- Start artificial tears/ocular lubricants for mild symptoms
- Rule out infectious causes if discharge present
- Document carefully as this would represent an unusual adverse event
Ophthalmology referral if:
- Symptoms persist beyond 48 hours
- Any vision changes occur
- Signs of inflammation (redness, swelling, photophobia)
- Recurrent with subsequent injections
Important Caveats
The evidence provided primarily addresses immune checkpoint inhibitor-related ocular toxicities 3, 4 and dupilumab-related ocular surface disorders 5, which are not applicable to tezepelumab. These are different drug classes with distinct mechanisms and adverse event profiles.
Tezepelumab does not cause the immune-related ocular toxicities (uveitis, episcleritis) seen with checkpoint inhibitors, nor the conjunctivitis pattern seen with dupilumab. The anti-TSLP mechanism of tezepelumab differs fundamentally from these agents 6, 7, 8.
If eye pain genuinely correlates temporally with tezepelumab injections across multiple doses, this should be reported to pharmacovigilance systems as a potential novel adverse event, but alternative explanations should be thoroughly investigated first.